Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Language
  • +91 11 4925 6000
  • Request information
  • +91 11 4925 6000
  • Part of brands: |
IndiaIndia
  • Part of brands: |
  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS+ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • ALICE
      • Endometrio
      • Family POC
    • Patients
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS + ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • Family POC
      • ALICE
      • Endometrio
  • Diagnostic
  • About us
    • Igenomix Research
    • About Igenomix
  • ACADEMY
Genomics Precision Diagnostic > Newborn Screening

Newborn Screening

Igenomix Newborn Screening is a genetic test that analyzes 237 genes linked to more than 200 conditions.

  • Technical Overview
  • Criteria & Clasification
  • Genes & diseases
  • Documentation
  • Scientific evidence

Diseases with high prevalence rates

Detect actionable rare diseases and clarify ambiguous results

Selection of diseases according to evidence-based medicine

Availability and access to treatment

Overview
  • Newborn Screening
  • Benefits
  • Indications

Overview

  • Around 3%-4% of newborns are affected by a genetic condition.
  • Igenomix NBS identifies genetic disorders in newborn babies. 
  • Newborn screening is a mandatory public health program that provides all newborn with testing and follow-up health care for a variety of medical conditions.
  • Igenomix Newborn Screening Test is a comprehensive genetic test that analyzes 237 genes analyzed using Next Generation Sequencing (NGS) technologies allowing a direct approach of genetic disorders to reach an accurate diagnosis.
  • In addition, this test identifies if the child is a healthy carrier of any of these genetic alterations.

NBS provides an extended panel of disorders analyzed with NGS based technologies offering a wider coverage than NBS done by the NHS.

  • These genes are responsible for developmental, genetic and metabolic disorders that cause serious health problems starting in early childhood.
  • The ultimate benefit is an early intervention to prevent intellectual and physical disabilities as well as life-threatening illnesses.
  • More diseases can be seen than with a conventional heel prick test.
Know more

Goals of Conventional Newborn Screening (NBS)

The goals of newborn screening are:

  • Decrease morbidity and mortality of actionable diseases by performing an early intervention to improve neonatal and long-term health outcomes.
  • Provide a universal health service of screening to all newborns.
  • Identifying screen-positive newborns
  • Diagnosing conditions
  • Communication with families
  • Referral to treatment centers
  • Follow up with long-term outcomes
  • Educating physicians and patients.

What is the procedure?

Benefits of Using NGS/Clinical Utility

IGX uses Next Generation Sequencing (NGS) technologies to perform NBS vs tandem mass spectrometry (MS-MS).

Benefits of using NGS:

  • Detect actionable rare diseases and clarify ambiguous results.
  • Improve prognostic utility and give a high diagnostic yield, more so in diseases with variable presentation.
  • Provide appropriate treatment to newborns.
  • Include pharmacogenetic services for a precision medicine-based treatment.
  • Genomic sequencing commonly used for diagnosis of rare disorders.
  • Newborn screening by genetic testing can reduce the frequency of false-positive results and provide the clinician with more information regarding the initial clinical evaluation.
  • The addition of DNA-based testing to primary NBS allows the diagnosis of conditions that could not be previously identified with a laboratory marker, given the nature of the technologies used.
  • Since NGS-WES technologies are used for the analysis, the patient’s data will be saved for the possibility of reanalysis as well as additional analysis at any stage of life.
  • Benefit for reproductive decisions and family planning in the case of a positive result.
  • Avoiding the development of symptoms and signs, some of which may be irreversible.
  • Analysis time:  
    • 20 days – 3 weeks with normal heel prick test (mass spectrometry)
    • 18-20 working days NBS IGX (NGS technology)

 Indication

  • It is a screening test of genetic actionable diseases indicated for all newborns.
  • Early treatment is crucial to prevent complications and improve prognosis of the newborns.

Test Limitations

  • Newborn screening DOES NOT replace the potential value of carrier genetic testing (CGT) nor does carrier genetic testing replace newborn screening.
  • Performed during the first days of life.
  • Buccal swab.
Criteria & Clasification

What has been included and why?

The disease included in the Newborn Screening have been selected given the following criteria:

  • Diseases with high prevalence rates
  • Detect actionable rare diseases and clarify ambiguous results
  • Selection of diseases according to evidence-based medicine
  • The benefits of screening must outweigh the risks
  • A feasibility of screening for the general population at a local and national level
  • Availability and access to treatment
  • Educating physicians and the public

Igenomix Newborn Screening vs current NBS

NBS test incorporates all diseases from conventional newborn screening (heel prick test) as well as Recommended Uniform Screening Panel (RUSP) and more:

The diseases included in the Igenomix NBS test can be classified in the following groups. You can find an example of a disease included in each group and its management.

Disease Group

Disorder

Signs and Symptoms

Patient Management

Result

Metabolic

Maple Syrup Urine Disease

Characterized by poor feeding, lethargy, vomiting, a maple syrup odor in the cerumen and urine, encephalopathy and central respiratory failure if untreated.

Dietary therapy to reduce toxic metabolites and achieve plasma concentrations of missing amino acids.

Asymptomatic normal life

Immunodeficiency

Severe Combined Immunodeficiency (SCID)

 

Presentation due to recurrent, increasingly severe infections with opportunistic organisms and failure to thrive.

Protective measures of prophylaxis with antibiotics, antifungals, antivirals and antibody replacement

Reduce the incidence of infections, slowing the progression and improve prognosis.

Neurology

Wilson Disease

Patients presents with abdominal pain, jaundice, hepatosplenomegaly, ascites, upper gastrointestinal bleed and mental status changes.

Early initiation of copper chelation

Reduce accumulation of copper and prevent irreversible damage.

Pulmonology

Cystic Fibrosis

Newborns present with rectal prolapse, meconium ileus, respiratory infections, pancreatic insufficiency, failure to thrive among other symptoms

Early initiation of pulmonary therapy, nutritional therapy, antibiotic prophylaxis, vaccination, bronchodilators

Decrease the incidence of infections, maintain pulmonary function. Reduce progression and improve prognosis

Endocrinology

Congenital hypothyroidism

Most infants are asymptomatic, those with symptoms typically present with lethargy, hoarse cry, feeding problems, constipation, myxoedema, macroglossia, among others.

Early initiation of thyroid hormone replacement (oral levothyroxine)

Prevent the development of impaired neurocognitive outcome, measured by intelligence quotient (IQ)

ENT

Hereditary Hearing Loss*

Infants will most likely remain asymptomatic until early childhood where the patient will have trouble understanding words, hearing consonants, avoidance of social setting etc

Early initiation of hearing aids, speech therapy and language therapy

Prevent developmental and speech delay

Hemoglobinopathies

Sickle cell anemia

Newborns can present with severe anemia, vaso-occlusive crisis, chronic abdominal pain, hyposplenism and infections.

Early initiation of primary prevention of acute complications, as well as hematopoietic stem cell transplantation

Prevent recurrent acute vaso-occlusive episodes and with successful hematopoietic stem cell transplantation achieve a normal asymptomatic life

Neuromuscular

Spinal Muscular Atrophy

Characterized by diffuse symmetric proximal muscle weakness greater in lower than upper extremities with absent or markedly decreased deep tendon reflexes.

Early initiation of disease-modifying therapy and supportive therapy

Improve quality of life and increase survival of affected individuals

Genes & Diseases
Documentation
  • Specialists’ documents

Clinical Sheet

Download

Brochure

Download

Gene List

Download

Reports Guidelines

Download
Scientific evidence

Relevant related studies:

ACOG Committee Opinion No. 778 Summary: Newborn Screening and the Role of the Obstetrician–Gynecologist. (2019). Obstetrics & Gynecology, 133(5), 1073-1074. doi: 10.1097/aog.0000000000003246

https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html#:~:text=The%20RUSP%20is%20a%20list,newborn%20screening%20(NBS)%20programs

van Campen, Sollars, Thomas, Bartlett, Milano, & Parker et al. (2019). Next Generation Sequencing in Newborn Screening in the United Kingdom National Health Service. International Journal Of Neonatal Screening, 5(4), 40. doi: 10.3390/ijns5040040

Adhikari, A. N., Gallagher, R. C., Wang, Y., Currier, R. J., Amatuni, G., Bassaganyas, L., Chen, F., Kundu, K., Kvale, M., Mooney, S. D., Nussbaum, R. L., Randi, S. S., Sanford, J., Shieh, J. T., Srinivasan, R., Sunderam, U., Tang, H., Vaka, D., Zou, Y., Koenig, B. A., … Brenner, S. E. (2020). The role of exome sequencing in newborn screening for inborn errors of metabolism. Nature medicine, 26(9), 1392–1397. https://doi.org/10.1038/s41591-020-0966-5

Rajabi, F. (2018). Updates in Newborn Screening. Pediatric Annals, 47(5). doi: 10.3928/19382359-20180426-01

Wang, W., Yang, J., Xue, J., Mu, W., Zhang, X., Wu, W., Xu, M., Gong, Y., Liu, Y., Zhang, Y., Xie, X., Gu, W., Bai, J., & Cram, D. S. (2019). A comprehensive multiplex PCR based exome-sequencing assay for rapid bloodspot confirmation of inborn errors of metabolism. BMC medical genetics, 20(1), 3. https://doi.org/10.1186/s12881-018-0731-5

Waisbren, S., Bäck, D., Liu, C., Kalia, S., Ringer, S., Holm, I., & Green, R. (2014). Parents are interested in newborn genomic testing during the early postpartum period. Genetics In Medicine, 17(6), 501-504. doi: 10.1038/gim.2014.139 

Pereira, S., Robinson, J. O., Gutierrez, A. M., Petersen, D. K., Hsu, R. L., Lee, C. H., Schwartz, T. S., Holm, I. A., Beggs, A. H., Green, R. C., McGuire, A. L., & BabySeq Project Group (2019). Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project. Pediatrics, 143(Suppl 1), S6–S13. https://doi.org/10.1542/peds.2018-1099C

 


FAQs

Opening hours, contact details, lab address...

User manual

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

Learn more about Igenomix

Other services

NACE

Minimizes unnecessary amniocentesis

More information

CGT

Determines the risk of having a child with a genetic disease

More information

POC

Checks whether a miscarriage was the result of an aneuploidy

More information

Igenomix is in the media

IGENOMIX has not affiliated any news outlet or publication identified above. News coverage does not constitute an endorsement of IGENOMIX or its products

IGENOMIX_PartOfVitrolifeGroup_black

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

OUR SERVICES

Genetic solutions
Learn about genetics
How to send a sample

ABOUT US

About Igenomix
Contact
Quality
Work with us

FOLLOW IGENOMIX

Blog: Path to fertility

  +91 11 4925 6000
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Language

[2024] © Igenomix Privacy policy Quality policy Legal note Cookies policy




  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS+ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • ALICE
      • Endometrio
      • Family POC
    • Patients
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS + ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • Family POC
      • ALICE
      • Endometrio
  • Diagnostic
  • About us
    • Igenomix Research
    • About Igenomix
  • ACADEMY
  • Language
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT